Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - jamanetwork.com
Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …
被引用次数：383 相关文章

[引用][C] Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - cir.nii.ac.jp
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in
Patients With Early Alzheimer Disease | CiNii Research CiNii 国立情報学研究所 学術情報 …

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof… - JAMA …, 2022 - pubmed.ncbi.nlm.nih.gov
Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …
[PDF] championsforhealth.org

[PDF][PDF] Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof, P Burkett, J Barakos… - championsforhealth.org
OBJECTIVE To describe the radiographic and clinical characteristics of ARIA that occurred
in EMERGE and ENGAGE. DESIGN, SETTING, AND PARTICIPANTS Secondary analysis of …
[PDF] globalneurologyacademy.org

[PDF][PDF] Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof, P Burkett, J Barakos… - cdn.globalneurologyacademy.org
OBJECTIVE To describe the radiographic and clinical characteristics of ARIA that occurred
in EMERGE and ENGAGE. DESIGN, SETTING, AND PARTICIPANTS Secondary analysis of …

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof… - JAMA …, 2022 - researchinformation.amsterdamumc …
Abstract Importance: The EMERGE and ENGAGE phase 3 randomized clinical trials of
aducanumab provide a robust data set to characterize amyloid-related imaging …

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - search.ebscohost.com
Abstract Key Points: Question: What are the characteristics of amyloid-related imaging
abnormalities (ARIA) during aducanumab treatment in individuals with early Alzheimer …

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - europepmc.org
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in
Patients With Early Alzheimer Disease. - Abstract - Europe PMC Sign in | Create an account …

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2021 - discovery.ucl.ac.uk
Importance: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …
[HTML] nih.gov

[HTML][HTML] Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - ncbi.nlm.nih.gov
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in
Patients With Early Alzheimer Disease - PMC Back to Top Skip to main content NIH NLM Logo …